B of A Securities Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $31
Portfolio Pulse from vivek@benzinga.com
B of A Securities analyst Jason Zemansky maintains a Buy rating on Syndax Pharmaceuticals (NASDAQ:SNDX) and raises the price target from $30 to $31.
August 15, 2024 | 5:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
B of A Securities analyst Jason Zemansky maintains a Buy rating on Syndax Pharmaceuticals and raises the price target from $30 to $31.
The Buy rating and increased price target from a reputable analyst at B of A Securities is likely to positively influence investor sentiment and drive short-term price appreciation for Syndax Pharmaceuticals.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100